Proton therapy developer Ion Beam Applications (IBA) has signed collaborative research and technology license agreements with the University of Iowa to develop ultrahigh-precision intensity-modulated proton therapy (IMPT).
The agreement includes an exclusive license to the university's Dynamic Collimation System (DCS), which is designed to enhance dose conformity in IMPT procedures.
IBA and the university said that clinical indications for DCS could extend to many tumor sites, and the technology is expected to improve hypofractionated treatments in proton therapy over the next five years.
